DMK PHARMACEUTICALS CORP (DMK)
US00547W3079 - Common Stock
Taking everything into account, DMK scores 2 out of 10 in our fundamental rating. DMK was compared to 196 industry peers in the Pharmaceuticals industry. DMK may be in some trouble as it scores bad on both profitability and health. DMK is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year DMK has reported negative net income.
DMK had a negative operating cash flow in the past year.
DMK had negative earnings in each of the past 5 years.
In the past 5 years DMK always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of DMK (-248.15%) is worse than 93.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -248.15% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-173.97%
ROA(5y)-129.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DMK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DMK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DMK remains at a similar level compared to 1 year ago.
DMK has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DMK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
DMK has an Altman-Z score of -60.09. This is a bad value and indicates that DMK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -60.09, DMK is not doing good in the industry: 94.55% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -60.09 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
A Current Ratio of 0.58 indicates that DMK may have some problems paying its short term obligations.
With a Current ratio value of 0.58, DMK is not doing good in the industry: 92.57% of the companies in the same industry are doing better.
DMK has a Quick Ratio of 0.58. This is a bad value and indicates that DMK is not financially healthy enough and could expect problems in meeting its short term obligations.
DMK's Quick ratio of 0.54 is on the low side compared to the rest of the industry. DMK is outperformed by 93.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.58 | ||
| Quick Ratio | 0.54 |
3. Growth
3.1 Past
DMK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.96%, which is quite impressive.
DMK shows a strong growth in Revenue. In the last year, the Revenue has grown by 160.36%.
DMK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.29% yearly.
EPS 1Y (TTM)37.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.73%
Revenue 1Y (TTM)160.36%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%-99.4%
3.2 Future
The Earnings Per Share is expected to grow by 25.25% on average over the next years. This is a very strong growth
Based on estimates for the next years, DMK will show a very strong growth in Revenue. The Revenue will grow by 53.75% on average per year.
EPS Next Y64.16%
EPS Next 2Y38.62%
EPS Next 3Y25.25%
EPS Next 5YN/A
Revenue Next Year-68.82%
Revenue Next 2Y-0.76%
Revenue Next 3Y53.75%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
DMK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DMK's earnings are expected to grow with 25.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y25.25%
5. Dividend
5.1 Amount
No dividends for DMK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DMK PHARMACEUTICALS CORP
NASDAQ:DMK (2/6/2024, 8:05:16 PM)
After market: 0.1665 -0.07 (-28.23%)0.232
+0 (+0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -248.15% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.58 | ||
| Quick Ratio | 0.54 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)37.96%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y64.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)160.36%
Revenue growth 3Y-40.07%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y